221 related articles for article (PubMed ID: 36721242)
41. Marine sponge-derived sipholane triterpenoids reverse P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells.
Abraham I; Jain S; Wu CP; Khanfar MA; Kuang Y; Dai CL; Shi Z; Chen X; Fu L; Ambudkar SV; El Sayed K; Chen ZS
Biochem Pharmacol; 2010 Nov; 80(10):1497-506. PubMed ID: 20696137
[TBL] [Abstract][Full Text] [Related]
42. Reduction in ABCG2 mRNA Expression in Human Immortalised Brain Microvascular Endothelial Cells by Ferric Ammonium Citrate is Mediated by Reactive Oxygen Species and Activation of ERK1/2 Signalling.
Newman SA; Short JL; Nicolazzo JA
Pharm Res; 2023 Mar; 40(3):651-660. PubMed ID: 36539667
[TBL] [Abstract][Full Text] [Related]
43. Effect of prostaglandin E2 on multidrug resistance transporters in human placental cells.
Mason CW; Lee GT; Dong Y; Zhou H; He L; Weiner CP
Drug Metab Dispos; 2014 Dec; 42(12):2077-86. PubMed ID: 25261564
[TBL] [Abstract][Full Text] [Related]
44. Reversal of drug resistance by JS-K and nitric oxide in ABCB1- and ABCG2-expressing multi-drug resistant human tumor cells.
Sinha BK; Perera L; Cannon RE
Biomed Pharmacother; 2019 Dec; 120():109468. PubMed ID: 31605952
[TBL] [Abstract][Full Text] [Related]
45. The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2).
Kannan P; Telu S; Shukla S; Ambudkar SV; Pike VW; Halldin C; Gottesman MM; Innis RB; Hall MD
ACS Chem Neurosci; 2011 Feb; 2(2):82-9. PubMed ID: 22778859
[TBL] [Abstract][Full Text] [Related]
46. Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/BCRP) expressed at the blood-brain barrier.
Eisenblätter T; Hüwel S; Galla HJ
Brain Res; 2003 May; 971(2):221-31. PubMed ID: 12706238
[TBL] [Abstract][Full Text] [Related]
47. Binding Site Interactions of Modulators of Breast Cancer Resistance Protein, Multidrug Resistance-Associated Protein 2, and P-Glycoprotein Activity.
Deng F; Ghemtio L; Grazhdankin E; Wipf P; Xhaard H; Kidron H
Mol Pharm; 2020 Jul; 17(7):2398-2410. PubMed ID: 32496785
[TBL] [Abstract][Full Text] [Related]
48. Breast Cancer Resistance Protein (BCRP/
Lye P; Bloise E; Nadeem L; Peng C; Gibb W; Ortiga-Carvalho TM; Lye SJ; Matthews SG
Cells; 2019 Sep; 8(10):. PubMed ID: 31561453
[TBL] [Abstract][Full Text] [Related]
49. A combo-strategy to improve brain delivery of antiepileptic drugs: Focus on BCRP and intranasal administration.
Gonçalves J; Silva S; Gouveia F; Bicker J; Falcão A; Alves G; Fortuna A
Int J Pharm; 2021 Jan; 593():120161. PubMed ID: 33307160
[TBL] [Abstract][Full Text] [Related]
50. [¹¹C]befloxatone brain kinetics is not influenced by Bcrp function at the blood-brain barrier: a PET study using Bcrp TGEM knockout rats.
Hosten B; Boisgard R; Jacob A; Goutal S; Saubaméa B; Dollé F; Scherrmann JM; Cisternino S; Tournier N
Eur J Pharm Sci; 2013 Nov; 50(3-4):520-5. PubMed ID: 23981334
[TBL] [Abstract][Full Text] [Related]
51. Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance protein.
Fujita Y; Noguchi K; Suzuki T; Katayama K; Sugimoto Y
BMC Res Notes; 2013 Nov; 6():445. PubMed ID: 24196382
[TBL] [Abstract][Full Text] [Related]
52. Insight into the cooperation of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood-brain barrier: a case study examining sorafenib efflux clearance.
Agarwal S; Elmquist WF
Mol Pharm; 2012 Mar; 9(3):678-84. PubMed ID: 22335402
[TBL] [Abstract][Full Text] [Related]
53. Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein.
Lee YJ; Kusuhara H; Jonker JW; Schinkel AH; Sugiyama Y
J Pharmacol Exp Ther; 2005 Jan; 312(1):44-52. PubMed ID: 15448171
[TBL] [Abstract][Full Text] [Related]
54. Novel chalcone and flavone derivatives as selective and dual inhibitors of the transport proteins ABCB1 and ABCG2.
Silbermann K; Shah CP; Sahu NU; Juvale K; Stefan SM; Kharkar PS; Wiese M
Eur J Med Chem; 2019 Feb; 164():193-213. PubMed ID: 30594677
[TBL] [Abstract][Full Text] [Related]
55. Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.
Nakanishi T; Ross DD
Chin J Cancer; 2012 Feb; 31(2):73-99. PubMed ID: 22098950
[TBL] [Abstract][Full Text] [Related]
56. PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.
Vlaming ML; Läppchen T; Jansen HT; Kivits S; van Driel A; van de Steeg E; van der Hoorn JW; Sio CF; Steinbach OC; DeGroot J
Nucl Med Biol; 2015 Nov; 42(11):833-41. PubMed ID: 26264927
[TBL] [Abstract][Full Text] [Related]
57. Developmental expression of multidrug resistance phosphoglycoprotein (P-gp) in the mouse fetal brain and glucocorticoid regulation.
Petropoulos S; Gibb W; Matthews SG
Brain Res; 2010 Oct; 1357():9-18. PubMed ID: 20709040
[TBL] [Abstract][Full Text] [Related]
58. Drug transport across the blood-brain barrier and the impact of breast cancer resistance protein (ABCG2).
Nicolazzo JA; Katneni K
Curr Top Med Chem; 2009; 9(2):130-47. PubMed ID: 19200001
[TBL] [Abstract][Full Text] [Related]
59. (18)F-FCWAY, a serotonin 1A receptor radioligand, is a substrate for efflux transport at the human blood-brain barrier.
Liow JS; Zoghbi SS; Hu S; Hall MD; Hines CS; Shetty HU; Araneta MD; Page EM; Pike VW; Kreisl WC; Herscovitch P; Gottesman MM; Theodore WH; Innis RB
Neuroimage; 2016 Sep; 138():134-140. PubMed ID: 27211474
[TBL] [Abstract][Full Text] [Related]
60. The WD repeat-containing protein 5 (WDR5) antagonist WDR5-0103 restores the efficacy of cytotoxic drugs in multidrug-resistant cancer cells overexpressing ABCB1 or ABCG2.
Wu CP; Hsieh YJ; Tseng HY; Huang YH; Li YQ; Hung TH; Wang SP; Wu YS
Biomed Pharmacother; 2022 Oct; 154():113663. PubMed ID: 36081287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]